Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Re-treatment Trial for Patients Previously Randomized Into the SL0003 and SL0004, Randomized, Double-blind, Placebo-controlled, Multi-center Studies of Epratuzumab in Patients With Systemic Lupus Erythematosus

NCT00383513 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00383513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00383513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Re-treatment Trial for Patients Previously Randomized Into the SL0003 and SL0004, Randomized, Double-blind, Placebo-controlled, Multi-center Studies of Epratuzumab in Patients With Systemic Lupus Erythematosus
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
January 31, 2012
Enrollment
29 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus